Core Viewpoint - Biodexa Pharmaceuticals has secured an exclusive license for OPB-171775, a novel molecular glue aimed at treating gastrointestinal stromal tumors (GIST), which is expected to address significant unmet medical needs in patients resistant to current therapies [1][12]. Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for rare diseases with unmet medical needs [14]. - The company is advancing a pipeline that includes eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, alongside MTX240 [14][16]. Product Details - MTX240, also known as OPB-171775, utilizes a unique molecular glue mechanism to induce targeted protein interactions, distinguishing it from conventional kinase inhibitors [3]. - The compound targets GIST by stabilizing SLFN12, which promotes apoptosis in cancer cells through a pathway independent of KIT signaling, potentially overcoming resistance mechanisms associated with existing therapies [5]. Clinical Rationale - GIST is primarily driven by mutations in the KIT receptor tyrosine kinase, with current treatments often leading to resistance due to secondary mutations or alternative signaling pathways [4]. - Approximately 10-15% of GIST patients are either primarily refractory or develop secondary resistance to available TKIs, highlighting the need for new therapeutic options [10]. Efficacy Evidence - In patient-derived xenograft (PDX) models, MTX240 demonstrated dose-dependent anti-tumor efficacy in TKI-resistant scenarios, regardless of KIT mutation status [6][9]. - The PDX models used in studies are more predictive of human clinical outcomes, bridging laboratory findings with potential clinical applications [9]. Market Potential - The global GIST market is valued at approximately USD 1.3 billion, with an expected annual growth rate of 6-10% through 2032, driven by increasing incidence and new treatment options for resistant cases [11]. - GIST qualifies for orphan drug designation, which may provide regulatory advantages and incentives for drug development [11]. Licensing Agreement - Under the licensing agreement, Biodexa holds exclusive rights to develop and commercialize MTX240 globally, except in Japan, where Otsuka retains rights [12]. - The agreement includes an upfront fee, development milestones, and tiered royalties on net sales in the mid-single digit range [12]. Intellectual Property - MTX240 is protected by composition of matter patents in the US, Europe, Japan, and other countries, extending through 2037 without any patent term extension [13].